Credit: Getty Images. Despite a warning from the FDA Adverse Event Reporting System, studies have found that SGLT2 inhibitor use is not associated with an increased risk of AKI. Using a sodium ...

ORLANDO — Use of adjunctive sodium-glucose cotransport (SGLT) inhibitors along with insulin could herald a new era of improved glycemic control in type 1 diabetes, but there is concern about ...

The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows ...

also found that alpha cells express the sodium–glucose cotransporters ... Why would a cotransport system that concentrates glucose be used to control glucagon secretion, which is important ...

"This stroke benefit has not been clearly seen" with any agent from the closely related sodium-glucose cotransport-2 (SGLT2) inhibitor class, and "the MACE benefit appeared very early," within 3 ...

SGLT2 inhibitors work in a different way to lower your blood sugar. They curb the action of proteins called "sodium-glucose cotransporter 2" that help your kidneys reabsorb glucose (sugar ...

in combination with empagliflozin (Jardiance ®), a sodium-glucose cotransport-2 (SGLT2) inhibitor, in patients with type 2 diabetes and non-alcoholic steatohepatitis (NASH). The Phase 2a study ...

In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes.

or sodium-glucose cotransport protein 2 (SGLT2) inhibitors. However, researchers discovered that less than 4% of these adults used GLP-1 RAs therapy who were eligible for it. Only about 5% of the ...